915 Stock Overview
Shandong Shanda Wit Science and Technology Co., Ltd.
Shandong Shanda Wit Science and Technology Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CN¥42.48|
|52 Week High||CN¥47.11|
|52 Week Low||CN¥23.86|
|1 Month Change||4.50%|
|3 Month Change||24.94%|
|1 Year Change||65.42%|
|3 Year Change||107.73%|
|5 Year Change||15.22%|
|Change since IPO||411.67%|
Recent News & Updates
|915||CN Pharmaceuticals||CN Market|
Return vs Industry: 000915 exceeded the CN Pharmaceuticals industry which returned -19% over the past year.
Return vs Market: 000915 exceeded the CN Market which returned -10.1% over the past year.
|915 Average Weekly Movement||7.8%|
|Pharmaceuticals Industry Average Movement||7.2%|
|Market Average Movement||7.2%|
|10% most volatile stocks in CN Market||10.1%|
|10% least volatile stocks in CN Market||5.1%|
Stable Share Price: 000915 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 000915's weekly volatility (8%) has been stable over the past year.
About the Company
Shandong Shanda Wit Science and Technology Co., Ltd. engages in the pharmaceutical and environment protection businesses in China. Its medical products include azithromycin granules, glycyrrhiza zinc granules, compound calcium carbonate, vitamin AD drops, epalrestat tablets, valsartan hydrochlorothiazide gums, roxithromycin, rosiglitazone tartrate tablets, and glimepiride tablets.
Shandong Shanda Wit Science and Technology Fundamentals Summary
|915 fundamental statistics|
Is 915 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|915 income statement (TTM)|
|Cost of Revenue||CN¥609.01m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||1.82|
|Net Profit Margin||19.94%|
How did 915 perform over the long term?See historical performance and comparison
1.9%Current Dividend Yield
Is 915 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 915?
Other financial metrics that can be useful for relative valuation.
|What is 915's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 915's PE Ratio compare to its peers?
|915 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: 000915 is good value based on its Price-To-Earnings Ratio (23.3x) compared to the peer average (29.1x).
Price to Earnings Ratio vs Industry
How does 915's PE Ratio compare vs other companies in the Chinese Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 000915 is good value based on its Price-To-Earnings Ratio (23.3x) compared to the CN Pharmaceuticals industry average (32.3x)
Price to Earnings Ratio vs Fair Ratio
What is 915's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||23.3x|
|Fair PE Ratio||30.3x|
Price-To-Earnings vs Fair Ratio: 000915 is good value based on its Price-To-Earnings Ratio (23.3x) compared to the estimated Fair Price-To-Earnings Ratio (30.3x).
Share Price vs Fair Value
What is the Fair Price of 915 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 000915 (CN¥42.48) is trading below our estimate of fair value (CN¥106.18)
Significantly Below Fair Value: 000915 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: 000915 is poor value based on its PEG Ratio (1.1x)
Discover undervalued companies
How is Shandong Shanda Wit Science and Technology forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 000915's forecast earnings growth (22.1% per year) is above the savings rate (3.3%).
Earnings vs Market: 000915's earnings (22.1% per year) are forecast to grow slower than the CN market (24% per year).
High Growth Earnings: 000915's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 000915's revenue (17.9% per year) is forecast to grow faster than the CN market (17.6% per year).
High Growth Revenue: 000915's revenue (17.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 000915's Return on Equity is forecast to be high in 3 years time (20%)
Discover growth companies
How has Shandong Shanda Wit Science and Technology performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 000915 has high quality earnings.
Growing Profit Margin: 000915's current net profit margins (19.9%) are higher than last year (17.6%).
Past Earnings Growth Analysis
Earnings Trend: 000915's earnings have grown by 15.9% per year over the past 5 years.
Accelerating Growth: 000915's earnings growth over the past year (22%) exceeds its 5-year average (15.9% per year).
Earnings vs Industry: 000915 earnings growth over the past year (22%) exceeded the Pharmaceuticals industry 6.6%.
Return on Equity
High ROE: 000915's Return on Equity (21.4%) is considered high.
Discover strong past performing companies
How is Shandong Shanda Wit Science and Technology's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 000915's short term assets (CN¥2.8B) exceed its short term liabilities (CN¥533.3M).
Long Term Liabilities: 000915's short term assets (CN¥2.8B) exceed its long term liabilities (CN¥90.5M).
Debt to Equity History and Analysis
Debt Level: 000915 has more cash than its total debt.
Reducing Debt: 000915's debt to equity ratio has reduced from 1.4% to 0.3% over the past 5 years.
Debt Coverage: 000915's debt is well covered by operating cash flow (9425.7%).
Interest Coverage: 000915 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Shandong Shanda Wit Science and Technology current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 000915's dividend (1.88%) is higher than the bottom 25% of dividend payers in the CN market (0.48%).
High Dividend: 000915's dividend (1.88%) is low compared to the top 25% of dividend payers in the CN market (1.93%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 000915 has been paying a dividend for less than 10 years.
Growing Dividend: 000915's dividend payments have increased, but the company has only paid a dividend for 9 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (44%), 000915's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (23.9%), 000915's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jie Yang (59 yo)
Ms. Jie Yang served as a Vice Chairman of The Board of Directors at Shandong Shanda WIT Science & Technology Co., Ltd and has been its Director since May 16, 2012. Ms. Yang serves as Managing Director of...
Experienced Board: 000915's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Shandong Shanda Wit Science and Technology Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Shandong Shanda Wit Science and Technology Co., Ltd.
- Ticker: 915
- Exchange: SZSE
- Founded: 1993
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CN¥9.954b
- Shares outstanding: 234.33m
- Website: https://www.sd-wit.com
Number of Employees
- Shandong Shanda Wit Science and Technology Co., Ltd.
- Walter Plaza
- 4th Floor
- Shandong Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.